Day 2 :
Taijiao Jiang has completed his PhD in Biochemistry and Molecular Biology at the Institute of Biochemistry and Cell Biology-Chinese Academy of Sciences in 1999 and his Master Degree in Computer Science from Yale University in 2003. After his Postdoc researches in Yale Biology Department (1999-2002) and MIT Biology Department (2003-2005), he got a Professorship at Institute of Biophysics Chinese Academy of Sciences. In 2015, he joined at the Chinese Academy of Medical Sciences & Peking Union Medical College and cofounded the Suzhou Institute of Systems Medicine. He is the Director of Center of Biomedical Big Data of Chinese Academy of Medical Sciences. He has published more than 40 papers in reputed journals and has been serving as the President of Bioinformatics Branch of the Chinese Biophysics Society since 2017.
Due to the development of high throughput sequencing technologies, large-scale sequencing of pathogens, such as influenza viruses and HIV, has not only become a routine work in surveillance of infectious diseases, but also become indispensable in identification of newly emerging infectious disease in their outbreaks. Besides, analyses of these large-scale sequence data of pathogens will significantly enhance our understanding towards the evolution of diseases, promoting new strategies for prevention and control of these viruses. His research mainly focuses on modeling the evolution of infectious disease from gene data and epidemiological data. Many computational methods have been developed in his lab to understand the origin and evolution of influenza viruses. They were demonstrated to be helpful in influenza vaccine recommendation, estimating the mortality burden and disease lethality, sourcing newly emerging influenza viruses, and so on. They have made a significant influence in the field of bioinformatics and informatics of infectious diseases. Among them, in collaboration with China CDC, the new methods developed for vaccine recommendation of human influenza viruses have now been in use in China CDC for assisting flu vaccine strains selection.